{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:53:36Z","timestamp":1769572416303,"version":"3.49.0"},"reference-count":79,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tour de Cure grant","award":["RSP-080-19\/20"],"award-info":[{"award-number":["RSP-080-19\/20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a deadly thoracic malignancy and existing treatment options are limited. Chemotherapy remains the most widely used first-line treatment regimen for patients with unresectable MPM, but is hampered by drug resistance issues. The current study demonstrated a modest enhancement of MPM cell sensitivity to chemotherapy drug treatment following microRNA (miRNA) transfection in MPM cell lines, albeit not for all tested miRNAs. This effect was more pronounced for FAK (PND-1186) small molecule inhibitor treatment; consistent with previously published data. We previously established that MPM response to survivin (YM155) small molecule inhibitor treatment is unrelated to basal survivin expression. Here, we showed that MPM response to YM155 treatment is enhanced following miRNA transfection of YM155-resistant MPM cells. We determined that YM155-resistant MPM cells secrete a higher level of exosomes in comparison to YM155-sensitive MPM cells. Despite this, an exosome inhibitor (GW4896) did not enhance MPM cell sensitivity to YM155. Additionally, our study showed no evidence of a correlation between the mRNA expression of inhibitor of apoptosis (IAP) gene family members and MPM cell sensitivity to YM155. However, two drug transporter genes, ABCA6 and ABCA10, were upregulated in the MPM cell lines and correlated with poor sensitivity to YM155.<\/jats:p>","DOI":"10.3390\/cancers14194784","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:07:43Z","timestamp":1665187663000},"page":"4784","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploring MicroRNA and Exosome Involvement in Malignant Pleural Mesothelioma Drug Response"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-6281","authenticated-orcid":false,"given":"Ben","family":"Johnson","sequence":"first","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-5236","authenticated-orcid":false,"given":"Emma M.","family":"Rath","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"},{"name":"Giannoulatou Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia"},{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man Lee","family":"Yuen","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngan Ching","family":"Cheng","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaikai","family":"Shi","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"},{"name":"Chris O\u2019Brien Life House, Sydney, NSW 2050, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-5223","authenticated-orcid":false,"given":"Glen","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Pathology, Otago Medical School, University of Otago, Dunedin 9016, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuen Yee","family":"Cheng","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1038\/srep06152","article-title":"Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma","volume":"4","author":"Hudson","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.omtn.2017.07.001","article-title":"MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma","volume":"8","author":"Moody","year":"2017","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: A major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1013156407224","article-title":"Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies","volume":"20","author":"Hazlehurst","year":"2001","journal-title":"Cancer Metastasis Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3892\/br.2013.103","article-title":"Mesenchymal stem cells in the tumor microenvironment","volume":"1","author":"Guan","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-019-0970-x","article-title":"Therapy resistance mediated by exosomes","volume":"18","author":"Steinbichler","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_11","first-page":"98","article-title":"Exosome\/microvesicle-mediated epigenetic reprogramming of cells","volume":"1","author":"Camussi","year":"2010","journal-title":"Am. J. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ncb3169","article-title":"Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver","volume":"17","author":"Aiello","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nm.2753","article-title":"Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET","volume":"18","author":"Peinado","year":"2012","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/carcin\/bgu130","article-title":"Exosome-derived miRNAs and ovarian carcinoma progression","volume":"35","author":"Vaksman","year":"2014","journal-title":"Carcinogenesis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ra63","DOI":"10.1126\/scisignal.2005231","article-title":"Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells","volume":"7","author":"Ono","year":"2014","journal-title":"Sci. Signal."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"32643","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63739-X","article-title":"Proteomic analysis of exosomes secreted by human mesothelioma cells","volume":"164","author":"Hegmans","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21873\/cgp.20023","article-title":"A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ","volume":"14","author":"Creaney","year":"2017","journal-title":"Cancer Genom.\u2014Proteom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"743556","DOI":"10.3389\/fonc.2021.743556","article-title":"Exosomes: A New Pathway for Cancer Drug Resistance","volume":"11","author":"Zhong","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41419-020-03189-z","article-title":"Exosomes and breast cancer drug resistance","volume":"11","author":"Dong","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","article-title":"Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics","volume":"14","author":"Mita","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7183","DOI":"10.1158\/0008-5472.CAN-04-1918","article-title":"Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice","volume":"64","author":"Schimmer","year":"2004","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00432-011-1030-0","article-title":"BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients","volume":"137","author":"Hmeljak","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2004.10.003","article-title":"Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions","volume":"48","author":"Falleni","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/path.2121","article-title":"Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma","volume":"211","author":"Gordon","year":"2007","journal-title":"J. Pathol."},{"key":"ref_26","first-page":"453","article-title":"Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma","volume":"29","author":"Zaffaroni","year":"2007","journal-title":"Cell. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.humpath.2006.12.013","article-title":"Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma","volume":"38","author":"Kleinberg","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-07-0109","article-title":"Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer","volume":"13","author":"Als","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_29","first-page":"687","article-title":"Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides","volume":"1","author":"Xia","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/path.2120","article-title":"Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-\u03b1 in malignant pleural mesothelioma","volume":"211","author":"Gordon","year":"2007","journal-title":"J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ijrobp.2006.12.018","article-title":"Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests","volume":"67","author":"Kim","year":"2007","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1368-7646(02)00049-3","article-title":"Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions","volume":"5","author":"Zaffaroni","year":"2002","journal-title":"Drug Resist. Updat."},{"key":"ref_33","first-page":"316739","article-title":"Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma","volume":"2015","author":"Franko","year":"2015","journal-title":"Dis. Markers"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/2211536605666161208154633","article-title":"Exploring Mechanisms of MicroRNA Downregulation in Cancer","volume":"6","author":"Williams","year":"2017","journal-title":"Microrna"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/1535-7163.MCT-07-0009","article-title":"MicroRNA expression profiles for the NCI-60 cancer cell panel","volume":"6","author":"Blower","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_36","first-page":"1193","article-title":"Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways","volume":"2","author":"Williams","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1164\/rccm.201503-0461LE","article-title":"A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma","volume":"191","author":"Kao","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Yuen, M.L., Zhuang, L., Rath, E.M., Yu, T., Johnson, B., Sarun, K.H., Wang, Y., Kao, S., Linton, A., and Clarke, C.J. (2021). The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910225"},{"key":"ref_41","unstructured":"Schedlich, L.J., Cheng, Y.Y., Gattani, S., Cheng, N.C., Kirschner, M.B., van Zandwijk, N., and Reid, G. (2012, January 11\u201314). The survivin suppressant YM 155 selectively inhibits the growth of epithelioid malignant mesothelioma in vitro and in vivo. Proceedings of the 11th International Mesothelioma Interest Group (iMig), Boston, MA, USA."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijmm.2021.4950","article-title":"Overexpression of microRNA-486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1","volume":"47","author":"Pinelli","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/0003-4975(94)90090-6","article-title":"Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma","volume":"57","author":"Smythe","year":"1994","journal-title":"Ann. Thorac. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e3182a0840a","article-title":"ZIC1 Is silenced and has tumor suppressor function in malignant pleural mesothelioma","volume":"8","author":"Cheng","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Rath, E.M., Cheng, Y.Y., Pinese, M., Sarun, K.H., Hudson, A.L., Weir, C., Wang, Y.D., H\u00e5kansson, A.P., Howell, V.M., and Liu, G.-J. (2018). BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203003"},{"key":"ref_47","unstructured":"von Seggern, D.H. (2007). CRC Standard Curves and Surfaces with Mathematica, Chapman and Hall\/CRC. [2nd ed.]."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v043.i09","article-title":"Unifying Optimization Algorithms to Aid Software System Users: Optimx for R","volume":"43","author":"Nash","year":"2011","journal-title":"J. Stat. Softw."},{"key":"ref_49","unstructured":"R Core Team (2020). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1349-7006.2007.00538.x","article-title":"Mechanism of multidrug recognition by MDR1\/ABCB1","volume":"98","author":"Yasuhisa","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1182\/blood-2011-04-351239","article-title":"Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/hsz-2016-0308","article-title":"MicroRNAs are important regulators of drug resistance in colorectal cancer","volume":"398","author":"Zhang","year":"2017","journal-title":"Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3892\/or.2013.2351","article-title":"Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells","volume":"29","author":"Tanaka","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_54","first-page":"6223","article-title":"Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma","volume":"35","author":"Andersen","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1038\/s41598-018-26050-y","article-title":"MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2174\/1389557515666150709115355","article-title":"MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy","volume":"15","author":"Mognato","year":"2015","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/13543776.2014.948845","article-title":"Focal adhesion kinase inhibitors in the treatment of metastatic cancer: A patent review","volume":"24","author":"Shanthi","year":"2014","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0074-7696(07)63003-4","article-title":"Focal adhesion kinase and p53 signaling in cancer cells","volume":"263","author":"Golubovskaya","year":"2007","journal-title":"Int. Rev. Cytol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10585-015-9752-z","article-title":"Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors","volume":"32","author":"Moen","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.18632\/oncotarget.6898","article-title":"Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-12-0167","article-title":"YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels","volume":"11","author":"Kumar","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","first-page":"20","article-title":"MicroRNA regulation and therapeutic targeting of survivin in cancer","volume":"5","author":"Huang","year":"2014","journal-title":"Am. J. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fonc.2018.00650","article-title":"MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review","volume":"8","author":"Russo","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13046-018-0906-0","article-title":"miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGF\u03b2 pathway","volume":"37","author":"Wang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ferrario, A., Luna, M., Rucker, N., Wong, S., Lederman, A., Kim, J., and Gomer, C. (2016). Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153011"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/annonc\/mdt249","article-title":"A phase I\/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"24","author":"Kelly","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","article-title":"Proteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions","volume":"31","author":"Bard","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"22492","DOI":"10.3402\/jev.v2i0.22492","article-title":"Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma","volume":"2","author":"Mahaweni","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"11688","DOI":"10.1038\/s41598-019-48133-0","article-title":"Exosomal miR-16-5p as a target for malignant mesothelioma","volume":"9","author":"Munson","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","article-title":"Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)","volume":"22","author":"Rathore","year":"2017","journal-title":"Apoptosis Int. J. Program. Cell Death"},{"key":"ref_75","first-page":"1796","article-title":"Expression and Prognostic Significance of IAP-Family Genes in Human Cancers and Myeloid Leukemias","volume":"6","author":"Tamm","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2019.10.004","article-title":"The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer","volume":"60","author":"Pasello","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00424-006-0047-8","article-title":"The ABCA subfamily\u2014Gene and protein structures, functions and associated hereditary diseases","volume":"453","author":"Albrecht","year":"2007","journal-title":"Pfl\u00fcgers Arch.\u2014Eur. J. Physiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8987","DOI":"10.1158\/0008-5472.CAN-04-1978","article-title":"Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes","volume":"64","author":"Gillet","year":"2004","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4784\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:20Z","timestamp":1760143460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":79,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194784"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194784","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}